NKCFO LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

NKCFO LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-142	Closed	-$110K	–	124
2026 Q1	$110K	Hold	142	–	–	0.03%	89
2025 Q4	$110K	Buy	+142	New	+$96.4K	0.03%	79

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

NKCFO LLC's REGN Position: Q2 2026 in Review

NKCFO LLC sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 142 shares — an estimated $110K sold.

NKCFO LLC first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $110K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

NKCFO LLC reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
NKCFO LLC sold 142 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $110K.
NKCFO LLC first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
NKCFO LLC's Regeneron Pharmaceuticals position peaked at $110K in Q1 2026.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on NKCFO LLC's 13F filing for Q2 2026, filed 13 Aug 2026.